References
- Chorzelski T. P., Jablonska S., Beutner E. H., Bean S. F., Furey N. L. Linear IgA bullous dermatosis. Immunopathology of the skin. Wiley Medical, New York 1987; 407–20
- Waldman M. A., Black D. R., Callen J. P. Vancomycin‐induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Exp Dermatol 2004; 29: 633–6
- Mutasim D. F. Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859–77
- Marzano A. V., Dassoni F., Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatol Treat 2006; 17: 370–6
- Farley‐Li J., Mancini A. J. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol 2003; 39: 1121–4
- Gläser R., Sticherling M. Successful treatment of linear IgA bullous dermatosis with mycophenolate mofetil. Acta Derm Venereol 2002; 82: 308–9
- Talhari C., Mahnke N., Ruzicka T., Megahed M. Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent. Clin Exp Dermatol 2005; 30: 294–307
- Allison A. C., Eugui E. M. Purine metabolism and the immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10((1 Pt 2))77–84
- Kitchin J. E., Pomeranz M. K., Pak G., Washenik K., Shupack J. L. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37((3 Pt 1))445–9
- Becker B. N. Mycophenolate mofetil. Transplant Proc 1999; 31: 2777–8